Lack of interaction of erythromycin with temazepam.
Erythromycin is a strong inhibitor of cytochrome P450 [CYP3A4] and has a potentially dangerous interaction with midazolam and triazolam. The possible interaction between erythromycin and a short-acting benzodiazepine, temazepam, was investigated in a double-blind, randomized crossover study. Ten healthy volunteers received 500 mg erythromycin or placebo orally three times a day for 6 days followed by a challenge dose of 20 mg temazepam. Plasma samples were collected for the determination of temazepam, oxazepam, and erythromycin, and psychomotor effects were measured during the 24 h after intake of temazepam. Erythromycin did not change the pharmacokinetics or pharmacodynamics of temazepam to a statistically significant degree. The metabolic fate of temazepam and its almost complete bioavailability explain the lack of interaction. Temazepam, unlike midazolam or triazolam, can thus be prescribed in the usual doses for patients receiving erythromycin.
Luurila
H
H
Department of Clinical Pharmacology, University of Helsinki, Finland.
Olkkola
K T
KT
Neuvonen
P J
PJ
D000284:Administration, Oral; D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004347:Drug Interactions; D004917:Erythromycin / Q000494:pharmacology*; D005260:Female; D005387:Finland; D006801:Humans; D008297:Male; D013607:Tablets; D013693:Temazepam / Q000493:pharmacokinetics / Q000494:pharmacology*
D013607:Tablets; D004917:Erythromycin; D013693:Temazepam